Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYO4
- Development stage
- Preclinical
- Lead developer
- Myocea
- Modality
- Small Molecules
01
Overview
MYO4 is a preclinical **small molecule** drug candidate being developed by **Myocea** for **spinal muscular atrophy**. Based on Myocea's pipeline, the program is positioned as an SMA skeletal muscle biology candidate with **integrin** as the stated target. The precise molecular mechanism, specific integrin subtype, binding mode, and pharmacologic effect have not been publicly disclosed, but the program appears intended to modulate integrin-related pathways relevant to muscle and neuromuscular junction biology in SMA.
- Other names
- MYO4-Myocea-Integrin-small molecule-Spinal Muscular AtrophyMYO-4-Myocea-Integrin-small molecule-Spinal Muscular AtrophyMYO 4-Myocea-Integrin-small molecule-Spinal Muscular Atrophy
02
Targets
ITGA4 (Integrin alpha-4)
Beyond the preview
Go deeper on MYO4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYO4.